A well-structured CCSÌýdemonstratesÌýto regulators that your organization takes contamination control seriously, understands its risks, and proactively manages them.Ìý
- EU Annex 1 ComplianceÌý– Annex 1 requires every manufacturer of sterile medicinal products toÌýestablishÌýand maintain a formal CCS that holistically addresses contamination prevention.Ìý
- FDA ExpectationsÌý– While the FDA does not require a formal CCS document, the same elements must be addressed in alignment with the 2004 aseptic processing guidance. Presenting this information in a structured CCSÌýdemonstratesÌýpreparedness and a mature quality culture.Ìý
By integrating your CCS into your overallÌýQuality Management System (QMS), you strengthen both regulatory readiness and operational performance.Ìý
While not mandated, the FDA’s aseptic processing guidance (2004) expects this information.ÌýEven if the product is not sterile, contamination can make it adulterated underÌýfederalÌýlaw.ÌýA CCS shows regulators you areÌýpreparedÌýand take contamination control seriously.ÌýÌý















